AC110619.2 | Uncharacterized protein | | | | | | Tissue enhanced |
ADAMTS6 | ADAM metallopeptidase with thrombospondin type 1 motif, 6 | Cancer-related genes Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
ADAMTSL4 | ADAMTS-like 4 | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
ADRB1 | Adrenoceptor beta 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
AFF2 | AF4/FMR2 family, member 2 | Disease related genes Plasma proteins
| | | | | Tissue enhanced |
AGTR1 | Angiotensin II receptor, type 1 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
AKR1B15 | Aldo-keto reductase family 1, member B15 | | | | | | Tissue enhanced |
ALPPL2 | Alkaline phosphatase, placental-like 2 | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
APLN | Apelin | Predicted secreted proteins
| | | | | Tissue enhanced |
APLNR | Apelin receptor | G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
AREG | Amphiregulin | Cancer-related genes Predicted membrane proteins
| | | | | Tissue enhanced |
AREGB | Amphiregulin B | Cancer-related genes Predicted membrane proteins
| | | | | Tissue enhanced |
ARID3A | AT rich interactive domain 3A (BRIGHT-like) | Transcription factors
| | | | | Tissue enhanced |
ATG9B | Autophagy related 9B | Predicted membrane proteins
| | | | | Tissue enhanced |
BIRC7 | Baculoviral IAP repeat containing 7 | | | | | | Tissue enhanced |
BMP5 | Bone morphogenetic protein 5 | Predicted membrane proteins
| | | | | Tissue enhanced |
C20orf202 | Chromosome 20 open reading frame 202 | | | | | | Tissue enhanced |
C5orf17 | Chromosome 5 open reading frame 17 | | | | | | Tissue enhanced |
CCNE1 | Cyclin E1 | Cancer-related genes
| | | | | Tissue enhanced |
CCSAP | Centriole, cilia and spindle-associated protein | | | | | | Tissue enhanced |
CDH5 | Cadherin 5, type 2 (vascular endothelium) | Cancer-related genes CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CGB7 | Chorionic gonadotropin, beta polypeptide 7 | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CLDN6 | Claudin 6 | Predicted membrane proteins
| | | | | Tissue enhanced |
CLEC1A | C-type lectin domain family 1, member A | Predicted membrane proteins
| | | | | Tissue enhanced |
COL11A1 | Collagen, type XI, alpha 1 | Cancer-related genes Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
COL15A1 | Collagen, type XV, alpha 1 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
COL4A1 | Collagen, type IV, alpha 1 | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
COL4A2 | Collagen, type IV, alpha 2 | Cancer-related genes Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
COLEC12 | Collectin sub-family member 12 | Predicted membrane proteins
| | | | | Tissue enhanced |
COX4I2 | Cytochrome c oxidase subunit IV isoform 2 (lung) | Disease related genes Mitochondrial proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CSF2RA | Colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CTB-167G5.5 | Uncharacterized protein | Predicted membrane proteins
| | | | | Tissue enhanced |
CTHRC1 | Collagen triple helix repeat containing 1 | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
CYSLTR2 | Cysteinyl leukotriene receptor 2 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CYTL1 | Cytokine-like 1 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
DACT2 | Dishevelled-binding antagonist of beta-catenin 2 | | | | | | Tissue enhanced |
DEPDC1B | DEP domain containing 1B | | | | | | Tissue enhanced |
DIO3 | Deiodinase, iodothyronine, type III | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
DKK1 | Dickkopf WNT signaling pathway inhibitor 1 | Predicted secreted proteins
| | | | | Tissue enhanced |
DLX3 | Distal-less homeobox 3 | Disease related genes Transcription factors
| | | | | Tissue enhanced |
DPRX | Divergent-paired related homeobox | Transcription factors
| | | | | Tissue enhanced |
DSCR4 | Down syndrome critical region gene 4 | | | | | | Tissue enhanced |
EFHD1 | EF-hand domain family, member D1 | | | | | | Tissue enhanced |
EGFR | Epidermal growth factor receptor | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ENDOU | Endonuclease, polyU-specific | Predicted secreted proteins
| | | | | Tissue enhanced |
ENPP1 | Ectonucleotide pyrophosphatase/phosphodiesterase 1 | CD markers Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
ERVMER34-1 | Endogenous retrovirus group MER34, member 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
F5 | Coagulation factor V (proaccelerin, labile factor) | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
FAM124B | Family with sequence similarity 124B | | | | | | Tissue enhanced |
FAM162B | Family with sequence similarity 162, member B | Predicted membrane proteins
| | | | | Tissue enhanced |